Time Analysis of Online Adaptive Magnetic Resonance-Guided Radiation Therapy Workflow According to Anatomical Sites.

Güngör G. , Serbez İ., Temur B., Gür G., Kayalılar N., Mustafayev T., ...Daha Fazla

Practical radiation oncology, 2020 (SCI Expanded İndekslerine Giren Dergi) identifier identifier


© 2020 American Society for Radiation OncologyPurpose: To document time analysis of detailed workflow steps for the online adaptive magnetic resonance–guided radiation therapy treatments (MRgRT) with the ViewRay MRIdian system and to identify the barriers to and solutions for shorter treatment times. Methods and Materials: A total of 154 patients were treated with the ViewRay MRIdian system between September 2018 and October 2019. The time process of MRgRT workflow steps of 962 fractions for 166 treatment sites was analyzed in terms of patient and online adaptive treatment (ART) characteristics. Results: Overall, 774 of 962 fractions were treated with online ART, and 83.2% of adaptive fractions were completed in less than 60 minutes. Sixty-three percent, 50.3%, and 4.2% of fractions were completed in less than 50 minutes, 45 minutes, and 30 minutes, respectively. Eight-point-three percent and 3% of fractions were completed in more than 70 minutes and 80 minutes, respectively. The median time (tmed) for ART workflow steps were as follows: (1) setup tmed: 5.0 minutes, (2) low-resolution scanning tmed: 1 minute, (3) high-resolution scanning tmed: 3 minutes, (4) online contouring tmed: 9 minutes, (5) reoptimization with online quality assurance tmed: 5 minutes, (6) real targeting tmed: 3 minutes, (7) beam delivery with gating tmed: 17 minutes, and (8) net total treatment time tmed: 45 minutes. The shortest and longest tmean rates of net total treatment time were 41.59 minutes and 64.43 minutes for upper-lung-lobe-located thoracic tumors and ultracentrally located thoracic tumors, respectively. Conclusions: To our knowledge, this is the first broad treatment-time analysis for online ART in the literature. Although treatment times are long due to human- and technology-related limitations, benefits offered by MRgRT might be clinically important. In the future, implementation of artificial intelligence segmentation, an increase in dose rate, and faster multileaf collimator and gantry speeds may lead to achieving shorter MRgRT treatments.